SightGlass Vision
SightGlass Vision creates new technologies and treatments to help tackle the global rise of myopia. Their work is based on unique contrast theory and supported by strong research. Founded in 2016, the company is now a joint venture between CooperCompanies and EssilorLuxottica, working to bring myopia management solutions to more people around the world.
SightGlass Vision myopia management products
Myopia management products listed by Myopia Profile have been specifically designed for myopia control or myopia management in children, and have some form of regulatory approval or marking for this form of use. They also have randomized controlled trial research data supporting their efficacy, unless otherwise noted. It is up to the individual eye care practitioner to be aware of regulatory requirements for prescribing in their country of practice, and also be aware that not all products are available in all countries.
SightGlass Vision DOT
The SightGlass Vision DOT lens is a first-line option for managing myopia in children. A one-year clinical trial has shown strong results in slowing myopia progression. Unlike other designs that use optical defocus, DOT lenses are based on contrast theory.
These lenses use Diffusion Optics Technology (DOT™), which contains thousands of tiny light-scattering elements, each about one tenth of a millimeter wide. Instead of creating peripheral defocus, the microdots soften contrast before it reaches the retina. This provides a more natural visual experience, similar to single vision lenses, while helping to slow eye growth.